In Focus channel feed – Endpoints News

In Focus channel feed

Big leases, bigger regrets: Biotech slump turns swanky offices from asset into liability

3 days ago

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Last week

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Last week

'Find a way, or make one': How two scientists hope to revitalize CRISPR's rare disease crisis

3 weeks ago

The inside story of how SalioGen, a startup trying to wrangle ‘jumping genes’ to make medicines, fell apart

4 weeks ago

US drugmakers increasingly look abroad for clinical trials as confidence in FDA wavers

4 weeks ago

Primate researchers cope with uncertainty as NIH appeals for payment cuts in court

Last month

‘People will die’: End of NIH grants guts work between academics and companies to counter next pandemic

Last month

Illumina was built on DNA. Its future could be biology’s next big wave

2 months ago

A California health tech company is letting AI run medical visits, from intake to diagnosis

2 months ago

Ahead of FDA decision, Alnylam faces the big question: Can it make money?

2 months ago

Inside NYC’s waitlist-only health tech club, where young professionals find both friends and jobs

2 months ago

Trump’s science crackdown hits rare disease research: ‘We need to sit down with Elon Musk’

2 months ago

Can Bill Anderson save Bayer?

2 months ago

Will CRISPR matter?

3 months ago

Drugmakers seize on biomarkers to test the FDA's rare disease shift

3 months ago

Trump blog: Federal agencies must give jobs back to fired probationary workers, judge rules

3 months ago

China's biotech boom is threatening US drugmakers' dominance

4 months ago

Broad Institute paper offers potential new framework for treating Huntington’s disease

4 months ago

How a duty to spend wisely on worker benefits could loosen PBMs' grip on drug prices

5 months ago

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

5 months ago

As 23andMe struggles, another genetic testing company bets on drug discovery

5 months ago

Lawmakers are poking holes in pharma's favorite new way to market medicines

6 months ago

A rare neurological disease is Sage’s last, best hope after failures in depression

6 months ago

12 3 4 Next page Last page